Description

LEFRA 20 MG

Indications

LEFRA 20 MG is primarily indicated for the treatment of rheumatoid arthritis in adults. It is also used in the management of psoriatic arthritis and as a disease-modifying antirheumatic drug (DMARD) in patients with active ankylosing spondylitis. The medication may be prescribed to help reduce the signs and symptoms of these inflammatory conditions, improve physical function, and slow the progression of joint damage.

Mechanism of Action

LEFRA 20 MG contains leflunomide, which is an immunomodulatory agent. The drug works by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), which is crucial for the de novo synthesis of pyrimidines. By blocking this enzyme, LEFRA reduces the proliferation of activated lymphocytes, particularly T and B cells, which play a significant role in the inflammatory process associated with autoimmune diseases. This action leads to a decrease in the production of pro-inflammatory cytokines, ultimately resulting in reduced inflammation and joint damage.

Pharmacological Properties

Leflunomide is well-absorbed after oral administration, with peak plasma concentrations typically occurring within 6 to 12 hours. The drug has a half-life of approximately 14 to 18 days, which allows for once-daily dosing. LEFRA is extensively metabolized in the liver to its active metabolite, A771726, which also contributes to its therapeutic effects. The drug is primarily excreted in urine and feces, and its pharmacokinetics can be influenced by factors such as liver function and concomitant medications.

Contraindications

LEFRA 20 MG is contraindicated in patients with a history of hypersensitivity to leflunomide or any of its components. It should not be used in individuals with severe liver impairment, as the drug is metabolized in the liver and may exacerbate hepatic conditions. Additionally, LEFRA is contraindicated during pregnancy due to the potential risk of teratogenic effects and should not be used by women who are breastfeeding.

Side Effects

Common side effects associated with LEFRA 20 MG include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Other reported side effects may include headache, dizziness, and rash. More serious adverse effects can occur, including hepatotoxicity, hypertension, and bone marrow suppression, which can lead to anemia, leukopenia, or thrombocytopenia. Patients should be monitored regularly for liver function and blood cell counts during treatment.

Dosage and Administration

The recommended starting dose of LEFRA 20 MG for adults is 100 mg once daily for the first three days, followed by a maintenance dose of 20 mg once daily. In some cases, a lower maintenance dose of 10 mg may be considered based on individual patient response and tolerability. It is essential to take LEFRA consistently at the same time each day to maintain even blood levels. Patients should be advised to swallow the tablet whole with water and not to crush or chew it.

Interactions

LEFRA 20 MG may interact with several medications, which can affect its efficacy and safety profile. Co-administration with other immunosuppressive agents, such as methotrexate or azathioprine, may increase the risk of infections and other adverse effects. Leflunomide can also interact with anticoagulants, potentially enhancing their effects and increasing the risk of bleeding. It is crucial for patients to inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before initiating treatment with LEFRA 20 MG, healthcare providers should assess the patient’s medical history, particularly regarding liver disease, hypertension, and any history of infections. Regular monitoring of liver function tests and complete blood counts is recommended during treatment. Patients should be counseled regarding the signs and symptoms of liver toxicity and advised to report any unusual symptoms such as jaundice, dark urine, or persistent abdominal pain. Women of childbearing age should be advised to use effective contraception during treatment and for at least two years after discontinuation of the drug.

Clinical Studies

Clinical studies have demonstrated the efficacy of LEFRA 20 MG in reducing the signs and symptoms of rheumatoid arthritis. In randomized controlled trials, patients receiving leflunomide showed significant improvements in disease activity scores and physical function compared to placebo groups. Additionally, studies have indicated that LEFRA can slow the progression of joint damage as assessed by radiographic changes. Long-term studies have also suggested that the safety profile of leflunomide remains favorable with continued use, although monitoring for adverse effects remains essential.

Conclusion

LEFRA 20 MG is an effective treatment option for patients with rheumatoid arthritis and other inflammatory conditions. Its unique mechanism of action and pharmacological properties contribute to its role as a DMARD. While it offers significant benefits in managing autoimmune diseases, careful consideration of contraindications, potential side effects, and drug interactions is necessary. Regular monitoring and patient education are vital to ensure safe and effective use of this medication.